Identification of EGFR kinase domain mutations among lung cancer patients in China: Implication for targeted cancer therapy

Cell Research

Volumn 15, Issue 3, 2005, Pages 212-217

  Qin, Bao Ming ^a   Chen, Xiao ^a   De Zhu, Jing ^b   Pei, Duan Qing ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor (EGFR); Lung cancer; Somatic mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; CHINA; EXON; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; PROTEIN TERTIARY STRUCTURE; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AMINO ACID SEQUENCE; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHINA; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 27844589038     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290289     Document Type: Article

References (11)

1. Minna JD, Gazdar AF, Sprang SR, Herz J. Cancer. A bull's eye for targeted lung cancer therapy. Science 2004; 304:1458-61.
2. Dowell JE, Minna JD. Chasing mutations in the epidermal growth factor in lung cancer. N Engl J Med 2005; 352:830-2.
3. Tanovic A, Alfaro V. Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 2004; 40:809-27.
4. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122:598-609.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
7. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10:8195-203.
8. Han SW, Kim TY, Hwang PG, et al. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib. J Clin Oncol 2005; Feb 14: Epub ahead of print, http://dx.doi.org/10.1200/JCO.2005.01.388
9. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919-23.
10. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97:339-46.
11. Sellers WR, Meyerson M. EGFR gene mutations: a call for global x global views of cancer. J Natl Cancer Inst 2005; 97:326-8.